Search Results - "Bever, CT"

Hematopoietic Progenitors Express Neural Genes by Goolsby, James, Marty, Marie C., Heletz, Dafna, Chiappelli, Joshua, Tashko, Gerti, Yarnell, Deborah, Fishman, Paul S., Dhib-Jalbut, Suhayl, Bever, Christopher T., Pessac, Bernard, Trisler, David

“…Bone marrow, or cells selected from bone marrow, were reported recently to give rise to cells with a neural phenotype after in vitro treatment with…”
Get full text

Increased cathepsin B activity in multiple sclerosis brain by Bever, Christopher T., Garver, Dennis W.

“…Cathepsin B (CB) activity was measured in aqueous extracts of frozen autopsy specimens of centrum semiovale from three MS patients, five control patients with…”
Get full text

Practice parameter: Treatment of nervous system lyme disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology by HALPERIN, J. J, SHAPIRO, E. D, LOGIGIAN, E, BELMAN, A. L, DOTEVALL, L, WORMSER, G. P, KRUPP, L, GRONSETH, G, BEVER, C. T

“…To provide evidence-based recommendations on the treatment of nervous system Lyme disease and post-Lyme syndrome. Three questions were addressed: 1) Which…”
Get full text

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial by Mikol, Daniel D, MD, Barkhof, Frederik, MD, Chang, Peter, PhD, Coyle, Patricia K, MD, Jeffery, Douglas R, MD, Schwid, Steven R, MD, Stubinski, Bettina, MD, Uitdehaag, Bernard MJ, MD

“…Summary Background Interferon beta-1a and glatiramer acetate are commonly prescribed for relapsing-remitting multiple sclerosis (RRMS), but no published…”
Get full text

Quality improvement in neurology: AAN Parkinson disease quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology by CHENG, E. M, TONN, S, SWAIN-ENG, R, FACTOR, S. A, WEINER, W. J, BEVER, C. T

“…Measuring the quality of health care is a fundamental step toward improving health care and is increasingly used in pay-for-performance initiatives and…”
Get full text

Clinical trials of interferons in multiple sclerosis. What have we learned? by Panitch, H S, Bever, Jr, C T

“…Although multiple sclerosis (MS) is generally believed to be an immune-mediated disease, conventional therapy with ACTH, corticosteroids, or immunosuppressive…”
Get more information

Interferon- γ induced increases in intracellular cathepsin B activity in THP-1 cells are dependent on RNA transcription by Li, Qingdi, Bever, Christopher T.

“…Interferon- γ (IFN- γ) treatment of human macrophages induces increased intracellular levels of cathepsin B (CB), a lysosomal cysteine proteinase which is…”
Get full text

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials by Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R, Agius, M, Arnason, BGW, Bethoux, FA, Bever, CT, Bowen, JD, Brown, TR, Dietrich, DW, Edwards, K, Freedman, MS, Freedman, M, Kachuck, NJ, Kaufman, MD, Keilson, M, Khan, O, Krupp, LB, Leist, TP, Lindsey, JW, Lublin, FD, Mass, MK, Mattson, D, McGowan, D, Naismith, R, O’Connell, C, Oger, JJ, Panitch, H, Picone, MA, Rammohan, KW, Schapiro, RT, Schwid, SR, Scott, T, Short, C, Thrower, BW, Vollmer, TL, Camac, A, Cooper, JA, Chumley, WF, Cross, A, Dunnigan, RT, Gitt, JS, Hillen, M, Jeffrey, DR, Khatri, BO, Kresa-Reahl, K, Moon, S, Preiningerova, J, Tullman, M, Weinstock-Guttman, B, Wynn, DR

“…Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release…”
Get full text

Endotoxin Induces Increased Intracellular Cathepsin B Activity in THP-1 Cells by Li, Qingdi, Falkler, William A., Bever, Christopher T.

“…Abstract Macrophage cathepsin B (CB) is implicated in tissue injury in inflammatory diseases. Lipopolysaccharide (LPS) is an activator of macrophages whose…”
Get full text

The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study by Bever, Jr, C T, Grattan, L, Panitch, H S, Johnson, K P

“…The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) for MS consisting of the selective reminding, 10/36 spatial recall, symbol digit modalities,…”
Get more information

Gamma interferon induced increases in intracellular cathepsin B activity in PMA primed THP-1 cells are blocked by inhibitors of protein kinase C by Li, Q, Bever, Jr, C T

“…Macrophage proteinases including cathepsin B (CB) are implicated in the tissue injury of inflammatory lesions. We have previously shown that interferon-gamma…”
Get more information

Interferon beta-1b in the treatment of multiple sclerosis : final outcome of the randomized controlled trial

Get full text

Short-duration robotic therapy in stroke patients with severe upper-limb motor impairment by Finley, Margaret A, Fasoli, Susan E, Dipietro, Laura, Ohlhoff, Jill, Macclellan, Leah, Meister, Christine, Whitall, Jill, Macko, Richard, Bever, Jr, Christopher T, Krebs, Hermano I, Hogan, Neville

“…Chronic motor deficits in the upper limb (UL) are a major contributor to disability following stroke. This study investigated the effect of short-duration…”
Get full text

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b : Experience during the first three years

Get full text

Robotic upper-limb neurorehabilitation in chronic stroke patients by Macclellan, Leah R, Bradham, Douglas D, Whitall, Jill, Volpe, Bruce, Wilson, P David, Ohlhoff, Jill, Meister, Christine, Hogan, Neville, Krebs, Hermano I, Bever, Jr, Christopher T

“…This pilot study tested the effectiveness of an intense, short-term upper-limb robotic therapy for improvement in motor outcomes among chronic stroke patients…”
Get full text

Activation of astrocytic lysosomal proteinases by factors released by mononuclear leukocytes by BEVER, C. T, SNYDER, D. S, ENDRES, R. O, MORGAN, K. D, POSTLETHWAITE, A, WHITAKER, J. N

“…Lysosomal proteinases are increased in the tissue lesions of experimental allergic encephalomyelitis and have been implicated in the degradation of myelin…”
Get full text

The cost of delaying treatment in multiple sclerosis: what is lost is not regained by Schwid, S R, Bever, Jr, C T

Get full text

Cathepsin D activity in human peripheral blood mononuclear leukocytes by BEVER, C. T. JR, MORGAN, K. D, WHITAKER, J. N

“…To investigate the cellular origins of cathepsin D (CD) in inflammatory lesions, the CD content of lymphocyte subsets, monocytes, and macrophages were…”
Get full text

Patients with clinically isolated syndromes suggestive of MS: does MRI allow earlier diagnosis? by Giovannoni, Gavin, Bever, Jr, Christopher T

Get full text

The effects of 4-aminopyridine in multiple sclerosis patients : results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial by BEVER, C. T, YOUNG, D, FOSSLER, M. J, DEVANE, J, JOHNSON, K. P, ANDERSON, P. A, KRUMHOLZ, A, CONWAY, R. N, LESLIE, J, EDDINGTON, N, PLAISANCE, K. I, PANITCH, H. S, DHIB-JALBUT, S

“…Because 4-aminopyridine (AP) improves residual deficits in some multiple sclerosis (MS) patients but has a narrow toxic-to-therapeutic margin, we compared the…”
Get full text